



HEALTH OUTCOMES ASSESSMENT OF AN INTERDISCIPLINARY PHARMACEUTICAL ONCO-HAEMATOLOGY COMMITTEE

<u>D. VIEDMA RAMA¹, O. RUIZ-MILLO¹, J. POLO DURÁN¹, S. GOMEZ ÁLVAREZ¹, M. CLIMENTE MARTÍ¹.</u>

¹ Pharmacy Department, Doctor Peset Univertisity Hospital, Valencia. Spain.

Contact data: viedma_dan@gva.es

Background and importance


Antineoplastic treatments with a high health and/or economic impact (HHEI) request in 'extraordinary' use situations demands interdisciplinary assessment by a specialised committee on pharmaceutical oncohaematology.

Aim and objectives

 To evaluate the use of antineoplastic treatments with a HHEI request in 'extraordinary' use situations from an Inter-Multidisciplinary Committee of Pharmaceutical Onco-Haematology (CIMOF).
To identify patients which clinical benefit similar outcomes to pivotal clinical trials.


Material and methods

A retrospective observational 4-year (01/01/20-30/12/23) study was conducted in a tertiary hospital. Follow-up was carried out until 01/10/2024.



Qualitative variables: frequencies (%) - Quantitative variables: mean (SD) or median (IQR) according

Kolmogorov-Smirnov test.



Éxitus/LES 48

Figure 1: Distribution of estimated clinical benefit according to ESMO clinical benefit scale.



Conclusion and relevance

The interdisciplinary assessment by the pharmaceutical onco-hematology committee proved effective in managing antineoplastic treatments with high health and economic impact, as evidenced by the significant clinical benefit observed in 52% of patients.

ATC CODE: L04 IMMUNOSUPPRESSANTS 4CPS-170

